17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

FOR IMMEDIATE RELEASE

Sun Pharma announces USFDA approval to market generic Exelon® Capsules

Company gets yet another 180 day marketing exclusivity on a first-to-file ANDA with para IV certification

Mumbai, October 23, 2007: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis Exelon®, rivastigmine tartrate capsules.

These generic rivastigmine capsules are AB-rated equivalent of Novartis Exelon® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 200 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon® with a para IV certification, shares a 180-day marketing exclusivity. In view of the ongoing litigation with Novartis on this product, the Company is evaluating all its launch options.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.

Exelon ® is a registered trademark of Novartis.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 6645 5605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 6645 5606
Mobile +91 98219 23797
E mail miradesai@sunpharma.com